PARP inhibitor olaparib has been recommended in NICE’s final draft guidance for early breast cancer and advanced prostate cancer. A“groundbreaking deal” between AstraZeneca and NHS England has enabled the National Institute for Health and Care Excellence (NICE) to recommend olaparib for adults...
Familial breast cancer: summary of updated NICE guidance. BMJ. 2013;346:f3829. doi:10.1136/bmj.f3829.Evans DG, Graham J, O'Connell S, Arnold S, Fitzsimmons D. Familial breast cancer: Summary of updated NICE guidance. BMJ 2013;346:f3829....
Cost-effectiveness watchdog NICE has recommended routine NHS use of two new therapies for women with advanced breast cancer – Gilead's Trodelvy and Novartis' Piqray – in England. In a statement, the health technology assessment (HTA) organisation sai
1、NICE draft guidance recommends new treatment option for people with early breast cancer 2、Roche's Kadcyla wins NICE backing in early breast cancer use
NICE recommends Oncotype DX to guide breast cancer therapy . .Health-policyMyelofibrosis, treatmentReimbursementRuxolitinib, therapeutic useSplenomegaly, treatmentIn the same guidance the routine use of three other tests − the IHC4, MammaPrint or Mammostrat − was not supported. However, NICE ...
Familial breast cancer | important-information-about-this-guidance | Guidance and guidelines | NICE As part of the Prostate Cancer guideline development process the National Collaborating Centre for Cancer (NCC-C) invited the National South West Public He... - NICE 被引量: 21发表: 0年 ...
1.https://www.nice.org.uk/news/article/nice-draft-guidance-does-not-recommend-pembrolizumab-plus-chemotherapy-for-triple-negative-breast-cancer 2. Sharma P. Biology and Management of Patients With Triple-Negative Breast Cancer. Oncologist. 2016;21(9):1050-1062. doi:10.1634/theoncologist.2016-006...
Updated guidance on acute otitis media from the National Institute for Health and Care Excellence (NICE) recommends that anaesthetic and analgesic ear drops be considered for initial treatment of acute otitis media (AOM). The update is intended to reduce antibiotic use. The current NICE guideline,...
1. https://www.nice.org.uk/news/article/nice-draft-guidance-does-not-recommend-pembrolizumab-plus-chemotherapy-for-triple-negative-breast-cancer 2. Sharma P. Biology and Management of Patients With Triple-Negative Breas...
参考资料:National Institute for Health and Care Excellence – final draft guidance – talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations. NICE. January 2024. Accessed January 22, 2024.